Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 10920 McKinley Drive, Tampa, FL 33612, USA; Department of Immunology, Moffitt Cancer Center and Research Institute, 10902 USF Magnolia Drive, Tampa, FL 33612, USA.
Hematol Oncol Clin North Am. 2021 Feb;35(1):73-84. doi: 10.1016/j.hoc.2020.08.012. Epub 2020 Oct 26.
as adjuvant therapy for high-risk melanoma was extensively studied in regimens that varied by dosage, route of administration, formulation, and therapy duration. The high-dose regimen (HDI) showed significant improvements in relapse-free survival (RFS) in 3 trials and overall survival (OS) in 2. Ipilimumab at 3 mg/kg demonstrated significant OS benefits compared with HDI and less toxicity compared with ipilimumab at 10 mg/kg. More recently, the standard of care has changed in favor of nivolumab and pembrolizumab and BRAF-MEK inhibitors dabrafenib plus trametinib (for BRAF mutated melanoma), based on significant RFS benefits and more favorable toxicity profiles.
高剂量方案（HDI）在 3 项试验中显著改善了无复发生存率（RFS），在 2 项试验中显著改善了总生存率（OS）。与 HDI 相比，3 mg/kg 的伊匹单抗显示出显著的 OS 益处，与 10 mg/kg 的伊匹单抗相比，毒性更小。最近，纳武单抗和派姆单抗以及 BRAF-MEK 抑制剂 dabrafenib 加 trametinib（用于 BRAF 突变黑色素瘤）已成为标准治疗方法，因为它们具有显著的 RFS 益处和更有利的毒性特征。
